Wolfram Syndrome
Recent clinical, regulatory, research and industry developments relating to this disease.
Genomics of Wolfram Syndrome 1 (WFS1).
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes2
- Optic Atrophy1
- Wolfram Syndrome1
Leading journals1
- Biomolecules1
Leading researchers1
- Kõks S1
Affiliations (unnormalised)2
- Centre for Molecular Medicine and Innovative Therapeutics1
- Perron Institute for Neurological and Translational Science1
Reference
Authoritative identity, definition & identifiers.
A hereditary condition characterized by multiple symptoms including those of DIABETES INSIPIDUS; DIABETES MELLITUS; OPTIC ATROPHY; and DEAFNESS. This syndrome is also known as DIDMOAD (first letter of each word) and is usually associated with VASOPRESSIN deficiency. It is caused by mutations in gene WFS1 encoding wolframin, a 100-kDa transmembrane protein.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.